Pembrolizumab +/- Bevacizumab for Recurrent GBM
Clinical trial NCT02337491 · COMPLETED
Trial details
- NCT number
- NCT02337491
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-09
- Primary completion
- 2016-08-28
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.